What is StemoniX?
StemoniX is at the forefront of neurotechnology, specializing in the creation of engineered human brain models that accurately mimic neurological processes such as memory, learning, and cognition. Their innovative CNS-3D and PNS-3D technologies and services integrate cutting-edge tissue engineering, neural interfacing, and artificial intelligence. This unique combination allows StemoniX to provide researchers and developers in neuroscience, drug discovery, and neurological therapies with powerful tools for advancing scientific understanding and therapeutic development. The company's focus on replicating biological complexity positions it as a key player in the future of brain research and treatment.
How much funding has StemoniX raised?
StemoniX has raised a total of $23.3M across 4 funding rounds:
Angel/Seed
$2.5M
Series A
$6M
Series B
$14.4M
Debt
$350K
Angel/Seed (2016): $2.5M, investors not publicly disclosed
Series A (2017): $6M led by Exponential.io
Series B (2019): $14.4M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Key Investors in StemoniX
Exponential.io
Exponential.io is an entity operating within the software industry, known for its engagement in technology ventures. Their investment in StemoniX suggests a strategic interest in the intersection of AI and biotechnology.
What's next for StemoniX?
With the recent major strategic investment and substantial overall capital raised, StemoniX is poised for significant expansion. The company's trajectory, marked by a progression from early-stage seed funding through Series A and Series B rounds to its latest financing, indicates a strong market validation and investor confidence. This capital infusion is expected to fuel further research and development, enhance product capabilities, and broaden market penetration. StemoniX's focus on enterprise-level applications suggests a strategic push towards commercialization and partnerships within the pharmaceutical and biotechnology industries, aiming to accelerate drug discovery and the development of novel neurological treatments.
See full StemoniX company page
